Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review

Bamgboye, Adeboye Olakunle, Oni, Isaac Oluwadamilare, Collier, Andrew · 2021 · European Journal of Clinical Pharmacology

Abstract

Purpose SGLT2-inhibitors (SGLT-2i) have been linked to the risk of potential life-threatening diabetic ketoacidosis (DKA). The U.S. Food and Drug Administration and the European Medicines Agency issued warnings in 2015 and 2016 respectively on the predisposing factors to the development of DKA in individuals on an SGLT2i. New predisposing factors to DKA are still being discovered with the use of SGLT-2i. The list by FDA and EMA is yet to be updated. This article aims to provide a holistic list that includes the newer factors that have been implicated in the development of DKA. The overall aim is to guide physicians in prescribing this class of drugs for type 2 diabetes mellitus (T2D). Method A search was done using PUBMED, Google Scholar, and Directory of Open Access Journals with the following words: SGLT-2 Inhibitors AND Ketoacidosis were entered. We included articles from 2000 to 2020, those in English, those involving any of the approved SGLT2i medications in T2D patients, and studies that focused on DKA linked to SGLT-2i. These articles were reviewed, and relevant data extracted and compiled. Results and conclusion The review has revealed that predisposing factors include (excess) alcohol consumption, female gender, starvation due to illness or fasting, withholding the use of SGLT2i for less than 48 h peri-operatively, and the existence of a variations in the expression of SGLT2 receptors. Patients should be advised on "sick day rules," and if a patient becomes unwell wh…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00228-020-03051-3

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 66 references

Research works printed but not linked: 2

  1. FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes. 2012 November. Available from: https:// www.astrazeneca.com/media-centre/press-releases/2012/FORXIGAdapagliflozin-now-approved-in-European-Union-for-treatment-of-type2-diabetes-14112012
  2. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of low-carbohydrate diets: a systematic review. 2003. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-Available from: https://www.ncbi.nlm.nih.gov/books/NBK69697/

Cited by

See all 54

Metadata

Authors
Bamgboye, A. O., Oni, I. O., & Collier, A.
Affiliations
  • Obafemi Awolowo University (NG)
  • Glasgow Caledonian University (GB)
Corresponding author
Bamgboye, Adeboye Olakunle
Venue
European Journal of Clinical Pharmacology
Published
2020-11-26
Volume
77
Issue
5
Pages
651-657
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
OpenAlex
W3107565517
Cited by
48
References
66
Citations by year
2026: 3 · 2025: 5 · 2024: 12 · 2023: 13 · 2022: 10 · 2021: 5
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • ResearchOnline (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
diabetic ketoacidosis, SGLT2 inhibitors, type 2 diabetes, predisposing factors, alcohol consumption, female sex, starvation, sick day rules, intercurrent illness, drug safety
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Alcohol Drinking, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Health Status, Humans, Hypoglycemic Agents, Insulin, Risk Factors, Sex Factors, Surgical Procedures, Operative, Diabetic Ketoacidosis, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. https://app.cochat.ai/papers/10.1007/s00228-020-03051-3
The paper
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021). Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-020-03051-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.